의료용 의약품 시장 : 유형별, 최종 사용자별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율 및 예측(2024-2032년)

REPORT HIGHLIGHT

Ethical Pharmaceuticals Market size was valued at USD 6,590.09 Million in 2023, expanding at a CAGR of 12.90% from 2024 to 2032.

Ethical Pharmaceuticals are established on the foundation of organizational ethics within the pharmaceutical industry, encompassing system compliance, accountability, and culture. These ethical standards are derived from legal mandates set by regulatory bodies. Ethical pharmaceuticals are tightly regulated substances used for diagnosing or treating diseases. The entire process of their development, testing, marketing, and distribution adheres to strict standards and regulations to guarantee their safety, effectiveness, and quality.

Ethical Pharmaceuticals Market- Market Dynamics

Growing unhealthy lifestyles and rising number of geriatrics around the world are projected to drive the growth of market

Elderly individuals commonly experience a range of health problems and rely on medications to manage age-related conditions, which may include arthritis, osteoporosis, and dementia, among others. The World Health Organization predicts that by 2050, 80% of older people will reside in low- and middle-income countries. Unhealthy lifestyles, characterized by poor eating habits, sedentary behaviors, and the use of tobacco and alcohol, contribute to the increasing prevalence of chronic diseases like diabetes, cardiovascular disorders, and respiratory ailments. According to the National Center for Biotechnology Information, physical inactivity rates vary globally, ranging from 43% in the United States of America and the Middle East to 17% in Southeast Asia. Additionally, the rapid economic development in emerging markets offers new opportunities for pharmaceutical companies to expand their market presence. However, challenges related to drug pricing and reimbursement may hinder the growth of this market.

Ethical Pharmaceuticals Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 12.90% over the forecast period (2024-2032)

Based on Type segmentation, Lipid Regulators was predicted to show maximum market share in the year 2023

Based on End-User segmentation, Pharmaceutical Companies was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Ethical Pharmaceuticals Market- Segmentation Analysis:

The Global Ethical Pharmaceuticals Market is segmented on the basis of Type, End-User and Region.

The market is segmented into seven categories according to Type: Lipid Regulators, ACE Inhibitors, Respiratory Agents, Narcotic Analgesics, Diuretics, Calcium Antagonists, Hormonal Contraceptives, and Others. Lipid Regulators are the leading category in the market. The ethical pharmaceuticals market for lipid regulators is essential in addressing cardiovascular risk and enhancing public health outcomes, however, it must address numerous ethical and regulatory issues to maximize its potential in a responsible manner.

The market is segmented into two categories according to their end-user: Hospitals & Clinics, Pharmaceutical Companies, and Others. The Hospitals & Clinics sector holds the largest share in the market. Hospitals and clinics play a crucial role in diagnosing diseases and recommending suitable medications. Ethical pharmaceuticals, which necessitate a prescription from a medical practitioner, form a significant part of the treatment protocols offered in these establishments.

Ethical Pharmaceuticals Market- Geographical Insights

Geographically, this market is spread across North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided based on the countries involved in business activities. The growth of the market is expected to be dominated by North America, primarily due to the increasing healthcare expenditures, especially in developed countries. Developed nations in North America allocate significant resources to healthcare, with a considerable portion of these resources directed towards pharmaceuticals. The rise in healthcare spending supports the demand for ethical pharmaceuticals, as these medications play a crucial role in managing various health conditions and improving patient outcomes. According to the Centers for Medicare & Medicaid Services, healthcare spending in the United States grew by 4.1 percent in 2022, reaching USD 4.5 trillion or USD 13,493 per person. Health spending accounted for 17.3 percent of the nation's Gross Domestic Product. Europe holds the second-largest region for market growth, primarily due to the increasing desire for safe and effective treatment regimens, as well as the rising incidences of diabetes, cancer, and blood pressure.

Ethical Pharmaceuticals Market- Competitive Landscape:

Pharmaceutical companies dedicate significant resources to research and development in order to create new medications that provide better therapeutic results compared to current treatments. Through innovation, companies can identify new drug targets, develop more efficient therapies, and enhance patient outcomes. Competition arises as companies strive to introduce groundbreaking products to the market swiftly and obtain market exclusivity via patents. Additionally, pharmaceutical companies allocate funds towards marketing and branding initiatives to increase product awareness among healthcare providers, patients, and caregivers. Marketing tactics may involve direct-to-consumer advertising, physician education, medical training programs, and support for scientific conferences.

Recent Developments:

Teva has made an announcement currently regarding its decision to strip its active-pharmaceutical ingredient section, known as TAPI. TAPI is a prominent player in the small-molecule API sector, employing around 4,300 individuals globally. The decision to divest TAPI will enable Teva to optimize its current and potential revenue streams, directing its focus towards growth and innovation through capital reallocation, and ultimately enhancing its ability to cater to the needs of patients.

March 13, 2023, The Ethisphere Institute has recently acknowledged 3M for its commitment to ethics and integrity in business practices and compliance for the 10th consecutive year. 3M is among the select few industrial companies worldwide to receive this prestigious recognition in the current year.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ETHICAL PHARMACEUTICALS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Teva Pharmaceutical Industries Ltd.

Mylan Pharmaceuticals Inc

3M Company

Accrux Ltd.

Access Pharmaceuticals Inc.

Novartis AG

Teikoku Pharma USA Inc

Hisamitsu Pharmaceutical

UCB

GlaxoSmithKline

Boehringer Ingelheim

Johnson & Johnson

Endo International

Purdue Pharma

Chrono Therapeutics

CeQur

Eli Lilly and Company

Merck & Co., Inc.

AstraZeneca

Bristol-Myers Squibb Company

Pfizer Inc.

Sanofi

Others

GLOBAL ETHICAL PHARMACEUTICALS MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

• Lipid Regulators
• ACE Inhibitors
• Respiratory Agents
• Narcotic Analgesics
• Diuretics
• Calcium Antagonists
• Hormonal Contraceptives
• Others

GLOBAL ETHICAL PHARMACEUTICALS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

• Hospitals & Clinics
• Pharmaceutical Companies
• Others

GLOBAL ETHICAL PHARMACEUTICALS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

• North America
• The U.S.
• Canada
• Europe
• Germany
• France
• Italy
• Spain
• United Kingdom
• Russia
• Netherlands
• Sweden
• Poland
• Rest of Europe
• Asia Pacific
• India
• China
• South Korea
• Japan
• Australia
• Thailand
• Indonesia
• Philippines
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• United Arab Emirates
• Israel
• Turkey
• Algeria
• Egypt
• Rest of MEA

Table of Contents

1.Ethical Pharmaceuticals Market Overview

• 1.1.Study Scope
• 1.2.Market Estimation Years

2.Executive Summary

• 2.1.Market Snippet
  • 2.1.1.Ethical Pharmaceuticals Market Snippet by Type
  • 2.1.2.Ethical Pharmaceuticals Market Snippet by End-User
  • 2.1.3.Ethical Pharmaceuticals Market Snippet by Country
  • 2.1.4.Ethical Pharmaceuticals Market Snippet by Region
• 2.2.Competitive Insights

3.Ethical Pharmaceuticals Key Market Trends

• 3.1.Ethical Pharmaceuticals Market Drivers
  • 3.1.1.Impact Analysis of Market Drivers
• 3.2.Ethical Pharmaceuticals Market Restraints
  • 3.2.1.Impact Analysis of Market Restraints
• 3.3.Ethical Pharmaceuticals Market Opportunities
• 3.4.Ethical Pharmaceuticals Market Future Trends

4.Ethical Pharmaceuticals Industry Study

• 4.1.PEST Analysis
• 4.2.Porter's Five Forces Analysis
• 4.3.Growth Prospect Mapping
• 4.4.Regulatory Framework Analysis

5.Ethical Pharmaceuticals Market: COVID-19 Impact Analysis

• 5.1.Pre-COVID-19 Impact Analysis
• 5.2.Post-COVID-19 Impact Analysis
  • 5.2.1.Top Performing Segments
  • 5.2.2.Marginal Growth Segments
  • 5.2.3.Top Looser Segments
  • 5.2.4.Marginal Loss Segments

6.Ethical Pharmaceuticals Market Landscape

• 6.1.Ethical Pharmaceuticals Market Share Analysis, 2023
• 6.2.Breakdown Data, by Key Manufacturer
  • 6.2.1.Established Players' Analysis
  • 6.2.2.Emerging Players' Analysis

7.Ethical Pharmaceuticals Market - By Type

• 7.1.Overview
  • 7.1.1.Segment Share Analysis, By Type, 2023 & 2032 (%)
  • 7.1.2.Lipid Regulators
  • 7.1.3.ACE Inhibitors
  • 7.1.4.Respiratory Agents
  • 7.1.5.Narcotic Analgesics
  • 7.1.6.Diuretics
  • 7.1.7.Calcium Antagonists
  • 7.1.8.Hormonal Contraceptives
  • 7.1.9.Others

8.Ethical Pharmaceuticals Market - By End-User

• 8.1.Overview
  • 8.1.1.Segment Share Analysis, By End-User, 2023 & 2032 (%)
  • 8.1.2.Hospitals & Clinics
  • 8.1.3.Pharmaceutical Companies
  • 8.1.4.Others

9.Ethical Pharmaceuticals Market- By Geography

• 9.1.Introduction
  • 9.1.1.Segment Share Analysis, By Geography, 2023 & 2032 (%)
• 9.2.North America
  • 9.2.1.Overview
  • 9.2.2.Ethical Pharmaceuticals Key Manufacturers in North America
  • 9.2.3.North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 9.2.4.North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  • 9.2.5.North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.2.6.U.S.
    • 9.2.6.1.Overview
    • 9.2.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.2.6.3.U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.2.6.4.U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.2.7.Canada
    • 9.2.7.1.Overview
    • 9.2.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.2.7.3.Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.2.7.4.Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
• 9.3.Europe
  • 9.3.1.Overview
  • 9.3.2.Ethical Pharmaceuticals Key Manufacturers in Europe
  • 9.3.3.Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 9.3.4.Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  • 9.3.5.Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.3.6.Germany
    • 9.3.6.1.Overview
    • 9.3.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.3.6.3.Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.3.6.4.Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.3.7.Italy
    • 9.3.7.1.Overview
    • 9.3.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.3.7.3.Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.3.7.4.Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.3.8.United Kingdom
    • 9.3.8.1.Overview
    • 9.3.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.3.8.3.United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.3.8.4.United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.3.9.France
    • 9.3.9.1.Overview
    • 9.3.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.3.9.3.France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.3.9.4.France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.3.10.Russia
    • 9.3.10.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.3.10.2.Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.3.10.3.Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.3.11.Netherlands
    • 9.3.11.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.3.11.2.Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.3.11.3.Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.3.12.Sweden
    • 9.3.12.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.3.12.2.Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.3.12.3.Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.3.13.Poland
    • 9.3.13.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.3.13.2.Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.3.13.3.Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.3.14.Rest of Europe
    • 9.3.14.1.Overview
    • 9.3.14.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.3.14.3.Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.3.14.4.Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
• 9.4.Asia Pacific (APAC)
  • 9.4.1.Overview
  • 9.4.2.Ethical Pharmaceuticals Key Manufacturers in Asia Pacific
  • 9.4.3.Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 9.4.4.Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  • 9.4.5.Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.4.6.India
    • 9.4.6.1.Overview
    • 9.4.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.4.6.3.India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.4.6.4.India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.4.7.China
    • 9.4.7.1.Overview
    • 9.4.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.4.7.3.China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.4.7.4.China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.4.8.Japan
    • 9.4.8.1.Overview
    • 9.4.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.4.8.3.Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.4.8.4.Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.4.9.South Korea
    • 9.4.9.1.Overview
    • 9.4.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.4.9.3.South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.4.9.4.South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.4.10.Australia
    • 9.4.10.1.Overview
    • 9.4.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.4.10.3.Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.4.10.4.Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.4.11.Thailand
    • 9.4.11.1.Overview
    • 9.4.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.4.11.3.Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.4.11.4.Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.4.12.Indonesia
    • 9.4.12.1.Overview
    • 9.4.12.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.4.12.3.Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.4.12.4.Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.4.13.Philippines
    • 9.4.13.1.Overview
    • 9.4.13.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.4.13.3.Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.4.13.4.Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.4.14.Rest of APAC
    • 9.4.14.1.Overview
    • 9.4.14.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.4.14.3.Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.4.14.4.Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
• 9.5.Latin America
  • 9.5.1.Overview
  • 9.5.2.Ethical Pharmaceuticals Key Manufacturers in Latin America
  • 9.5.3.Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 9.5.4.Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  • 9.5.5.Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.5.6.Brazil
    • 9.5.6.1.Overview
    • 9.5.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.5.6.3.Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.5.6.4.Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.5.7.Mexico
    • 9.5.7.1.Overview
    • 9.5.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.5.7.3.Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.5.7.4.Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.5.8.Argentina
    • 9.5.8.1.Overview
    • 9.5.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.5.8.3.Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.5.8.4.Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.5.9.Colombia
    • 9.5.9.1.Overview
    • 9.5.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.5.9.3.Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.5.9.4.Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.5.10.Rest of LATAM
    • 9.5.10.1.Overview
    • 9.5.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.5.10.3.Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.5.10.4.Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
• 9.6.Middle East and Africa
  • 9.6.1.Overview
  • 9.6.2.Ethical Pharmaceuticals Key Manufacturers in Middle East and Africa
  • 9.6.3.Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 9.6.4.Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  • 9.6.5.Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.6.6.Saudi Arabia
    • 9.6.6.1.Overview
    • 9.6.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.6.6.3.Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.6.6.4.Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.6.7.United Arab Emirates
    • 9.6.7.1.Overview
    • 9.6.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.6.7.3.United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.6.7.4.United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.6.8.Israel
    • 9.6.8.1.Overview
    • 9.6.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.6.8.3.Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.6.8.4.Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.6.9.Turkey
    • 9.6.9.1.Overview
    • 9.6.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.6.9.3.Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.6.9.4.Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.6.10.Algeria
    • 9.6.10.1.Overview
    • 9.6.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.6.10.3.Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.6.10.4.Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.6.11.Egypt
    • 9.6.11.1.Overview
    • 9.6.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.6.11.3.Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.6.11.4.Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 9.6.12.Rest of MEA
    • 9.6.12.1.Overview
    • 9.6.12.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 9.6.12.3.Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.6.12.4.Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

10.Key Vendor Analysis- Ethical Pharmaceuticals Industry

• 10.1.Competitive Dashboard
• 10.2.Company Profiles
  • 10.2.1.Teva Pharmaceutical Industries Ltd.
  • 10.2.2.Mylan Pharmaceuticals Inc
  • 10.2.3.3M Company
  • 10.2.4.Accrux Ltd.
  • 10.2.5.Access Pharmaceuticals Inc.
  • 10.2.6.Novartis AG
  • 10.2.7.Teikoku Pharma USA Inc
  • 10.2.8.Hisamitsu Pharmaceutical
  • 10.2.9.UCB
  • 10.2.10.GlaxoSmithKline
  • 10.2.11.Boehringer Ingelheim
  • 10.2.12.Johnson & Johnson
  • 10.2.13.Endo International
  • 10.2.14.Purdue Pharma
  • 10.2.15.Chrono Therapeutics
  • 10.2.16.CeQur
  • 10.2.17.Eli Lilly and Company
  • 10.2.18.Merck & Co., Inc.
  • 10.2.19.AstraZeneca
  • 10.2.20.Bristol-Myers Squibb Company
  • 10.2.21.Pfizer Inc.
  • 10.2.22.Sanofi
  • 10.2.23.Others

11.360 Degree Analyst View

12.Appendix

• 12.1.Research Methodology
• 12.2.References
• 12.3.Abbreviations
• 12.4.Disclaimer
• 12.5.Contact Us